eprintid: 10141797
rev_number: 26
eprint_status: archive
userid: 608
dir: disk0/10/14/17/97
datestamp: 2022-03-11 09:30:28
lastmod: 2022-03-11 09:30:28
status_changed: 2022-03-11 09:30:28
type: thesis
metadata_visibility: show
creators_name: Srivastava, Ankur
title: The Use Of Non-Invasive Fibrosis Markers In Stratification Care Pathways For The Management Of Chronic Liver Disease
ispublished: unpub
divisions: B02
divisions: C10
divisions: D17
divisions: G91
divisions: UCL
keywords: cirrhosis, early detection
note: Copyright © The Author 2021. Original content in this thesis is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) Licence (https://creativecommons.org/licenses/by-nc/4.0/). Any third-party copyright material present remains the property of its respective owner(s) and is licensed under its existing terms. Access may initially be restricted at the author’s request.
abstract: The health, societal and economic consequences of chronic liver disease (CLD) are substantial and increasing exponentially. Cirrhosis is typically detected in the latter stages when prognosis is poor. Timely diagnosis is hindered by reliance on non-discriminatory tests for fibrosis. I explored the role of non-invasive tests (NITs) of liver fibrosis in primary care to promote earlier disease detection. In this thesis, a systematic review revealed a paucity of published studies evaluating NIT in the community setting. A national survey demonstrated that UK specialists consider current fibrosis assessment methods to be sub-optimal, and NIT are important in improving disease stratification in primary care. To benchmark standard care, a one-year retrospective study of GP referrals for non-alcoholic fatty liver disease (NAFLD) established 93% of referrals to have non-significant fibrosis (Brunt ≤ F2) as assessed by liver specialists. Over two-thirds had a low-risk FIB-4 (<1.30) and could have avoided referral, although a quarter of patients with indeterminate FIB-4 (1.30 – 3.25) had significant liver fibrosis suggesting patients in this subgroup warrant further evaluation. As part of the Camden and Islington liver working group, I developed and evaluated a NAFLD pathway that employs FIB-4 and ELF to identify patients with advanced fibrosis or cirrhosis (Brunt ≥ F3 fibrosis). The pathway processed nearly 1500 patients over two years, resulting in a reduction in the proportion of total patients referred and an 81% decrease in referral of patients with non-significant fibrosis. The pathway achieved a 5-fold increase in the referral of patients with advanced fibrosis and 3-fold increase in the detection of liver cirrhosis. To further extrapolate these findings, I developed a probabilistic decision analytical model which tested FIB-4, ELF and fibroscan, either alone or in combination in primary care pathways. Cost consequence analyses revealed all strategies to be clinically effective and cost-saving compared to standard care.
date: 2022-01-28
date_type: published
oa_status: green
full_text_type: other
thesis_class: doctoral_open
thesis_award: Ph.D
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 1914278
lyricists_name: Srivastava, Ankur
lyricists_id: ASRIV14
actors_name: Barczynska, Patrycja
actors_id: PBARC91
actors_role: owner
full_text_status: public
pagerange: 1-419
pages: 419
event_title: UCL (University College London)
institution: UCL (University College London)
department: Institute for Liver and Digestive Health
thesis_type: Doctoral
citation:        Srivastava, Ankur;      (2022)    The Use Of Non-Invasive Fibrosis Markers In Stratification Care Pathways For The Management Of Chronic Liver Disease.                   Doctoral thesis  (Ph.D), UCL (University College London).     Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10141797/1/Ankur%20Srivastava%2014103661%20FINAL%20PhD%20thesis%2012.01.2022.pdf